Prevalence of Kaposi's sarcoma-associated herpesvirus among intravenous drug users： a systematic review and meta-analysis  

作　　者：Qiwen Fang Zhenqiu Liu Zhijie Zhang Yan Zeng Tiejun Zhang 

机构地区：[1]Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China [2]Key Laboratory of Public Health Safety, Fudan University, Ministry of Education, Shanghai 200032,China [3]Department of Biochemistry and Key Laboratory of Xinjiang Endemic and Ethnic Diseases, ShiheziUniversity School of Medicine, Shihezi 832002, China [4]Collaborative Innovation Center of Social Risks Governance in Health, Fudan University, Shanghai200032, China

出　　处：《Virologica Sinica》2017年第5期415-422,共8页中国病毒学（英文版）

基　　金：supported by the Natural Science Foundation of Shanghai (17ZR1401400);the Natural Science Foundation of China (grant no. 81772170, U603117);the Doctoral Fund of Ministry of Education of China (Grant No. 20120071120050)

摘　　要：Intravenous drug users(IDUs) have been demonstrated to be highly vulnerable to HIV/AIDS.Nevertheless, the prevalence of Kaposi's sarcoma associated herpesvirus(KSHV), an important co-infected agent with HIV, among this population remained obscure. We conducted a systematic review on the epidemiological features of KSHV among IDUs worldwide. Eligible studies were retrieved from 6 electronic databases(Pub Med, EMBASE, Web of Science, CBM, CNKI and Wanfang).We calculated the pooled prevalence and 95% confidence interval(CI) overall and among subgroups using either random-effects model or fixed-effects model depending on between-study heterogeneity. The potential publication bias was assessed by the Egger's test. A meta-regression analysis was performed to explore the sources of heterogeneity. Finally, twenty-two studies with a total sample of 7881 IDUs were included in the analysis. The pooled prevalence of KSHV was14.71%(95% CI 11.12%–19.46%) among IDUs. Specifically, KSHV prevalence was 10.86%(95% CI6.95%–16.96%) in HIV-negative IDUs, and 13.56%(95% CI 10.57%–17.38%) in HIV-positive IDUs.Moreover, prevalence among IDUs from the three continents involved in the current study was similar:16.10%(95%CI 7.73%–33.54%) in Asia; 14.22%(95%CI 8.96%–22.57%) in Europe and 14.06%(95%CI11.38%–17.37%) in America. Globally, IDUs are at higher risk of the KSHV infection when compared with the general population, regardless of geographical region or HIV-infection status.Intravenous drug users（IDUs） have been demonstrated to be highly vulnerable to HIV/AIDS.Nevertheless, the prevalence of Kaposi＇s sarcoma associated herpesvirus（KSHV）, an important co-infected agent with HIV, among this population remained obscure. We conducted a systematic review on the epidemiological features of KSHV among IDUs worldwide. Eligible studies were retrieved from 6 electronic databases（Pub Med, EMBASE, Web of Science, CBM, CNKI and Wanfang）.We calculated the pooled prevalence and 95% confidence interval（CI） overall and among subgroups using either random-effects model or fixed-effects model depending on between-study heterogeneity. The potential publication bias was assessed by the Egger＇s test. A meta-regression analysis was performed to explore the sources of heterogeneity. Finally, twenty-two studies with a total sample of 7881 IDUs were included in the analysis. The pooled prevalence of KSHV was14.71%（95% CI 11.12%–19.46%） among IDUs. Specifically, KSHV prevalence was 10.86%（95% CI6.95%–16.96%） in HIV-negative IDUs, and 13.56%（95% CI 10.57%–17.38%） in HIV-positive IDUs.Moreover, prevalence among IDUs from the three continents involved in the current study was similar：16.10%（95%CI 7.73%–33.54%） in Asia; 14.22%（95%CI 8.96%–22.57%） in Europe and 14.06%（95%CI11.38%–17.37%） in America. Globally, IDUs are at higher risk of the KSHV infection when compared with the general population, regardless of geographical region or HIV-infection status.

关 键 词：Kaposi’s sarcoma-associated herpesvirus(KSHV) PREVALENCE intravenous drug users(IDUs) 

分 类 号：R511[医药卫生—内科学] R749.64[医药卫生—临床医学]